Dr. Revadee Liam-Or
King’s College London,
Prolonged liver injury may result in liver failure for which the only effective treatment is transplantation. There are currently no efficient regenerative treatment options available. The therapeutic properties of extracellular vesicles (EVs) derived from MSCs have been demonstrated in studies of liver pathology. Herein, we found that harvested EVs generated under two different cultural supplementations were different in the protein corona (PC) profile. The enrichment of specific proteins in the PC layer was shown to affect EV’s pharmacokinetics and pharmacodynamics in distinctive manners in vivo. MSC-derived EVs could suppress liver fibrosis progression, evaluated in CCl4-induced liver fibrosis mice. Moreover, the formation of PC could be modulated to enhance EVs’ efficacy.
Dr. Revadee Liam-Or is a pharmaceutical researcher. She graduated from Mahidol University, Thailand, with a Doctor of Pharmacy degree. She then continued studying for a master’s degree in Pharmaceutical Technology at King’s College London (KCL). During her master’s, she joined Prof. Khuloud Al-Jamal’s lab working on nature-derived nanoparticles, called extracellular vesicles (EVs), to determine factors controlling their uptake in cells as drug delivery systems. Prof. Al-Jamal is Professor of Drug Delivery & Nanomedicine and Head of Medicines Development, King’s College London. Upon completing her master’s, Dr Liam-Or was awarded the PGR International Scholarship to complete her PhD studies in Pharmaceutical Science at KCL (success rate 1%). She has extensively developed experience in designing EV-based therapeutic tools. Her current project involves the exploration of mesenchymal stem cell-derived EVs for drug delivery systems and regenerative medicine.
Seminar Room 4,
G/F Laboratory Block,
LKS Faculty of Medicine Building,
21 Sassoon Road, Pokfulam
All are welcome